Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy. [electronic resource]
Producer: 20200504Description: 699-708 p. digitalISSN:- 2050-6406
- 2-Naphthylamine
- Aged
- Anilides -- therapeutic use
- Antiviral Agents -- therapeutic use
- Carbamates -- therapeutic use
- Carcinoma, Hepatocellular -- complications
- Chemoembolization, Therapeutic
- Cyclopropanes
- Hepatectomy
- Hepatitis C, Chronic -- complications
- Humans
- Lactams, Macrocyclic
- Liver Cirrhosis -- complications
- Liver Neoplasms -- complications
- Macrocyclic Compounds -- therapeutic use
- Middle Aged
- Neoplasm Recurrence, Local
- Proline -- analogs & derivatives
- Prospective Studies
- Radiofrequency Ablation
- Ribavirin -- therapeutic use
- Ritonavir -- therapeutic use
- Sulfonamides -- therapeutic use
- Treatment Outcome
- Uracil -- analogs & derivatives
- Valine
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.